Efficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.

Basit Öğe Kaydı
dc.contributor.authorAlbiges, Laurence
dc.contributor.authorPowles, Thomas
dc.contributor.authorSuarez, Cristina
dc.contributor.authorJalkanen, Katriina Johanna
dc.contributor.authorBurotto, Mauricio
dc.contributor.authorGhatalia, Pooja
dc.contributor.authorIacovelli, Roberto
dc.date.accessioned2025-11-16T19:34:31Z
dc.date.issued2025
dc.departmentİstanbul Medeniyet Üniversitesi
dc.description.abstract[Abstract Not Available]
dc.description.sponsorshipMerck Sharp Dohme Corp.; Merck & Co., Inc., Rahway, NJ, USA
dc.description.sponsorshipThis study was supported by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
dc.identifier.doi10.1200/JCO.2025.43.5_suppl.538
dc.identifier.endpage538
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue5_SUPPL
dc.identifier.startpage538
dc.identifier.urihttps://doi.org/10.1200/JCO.2025.43.5_suppl.538
dc.identifier.urihttps://hdl.handle.net/20.500.14730/15363
dc.identifier.volume43
dc.identifier.wosWOS:001454684700006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.ispartofJournal of Clinical Oncology
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250302
dc.titleEfficacy outcomes with belzutifan versus everolimus by baseline disease characteristics and burden subgroups in the phase 3 LITESPARK-005 study.
dc.typeConference Object

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu